AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00916500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCURRENT CHEMORADIATION (CISPLATIN)
Description: Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
Study NCT00485030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience-V
Description: everolimus-eluting stent
Study NCT04818996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: While calculating the energy of the Mediterranean diet applied to the individuals participating in the study, Mifflin-St. Jeor equation is used. The macronutrient composition of the Mediterranean diet was calculated as 36-40% fat, 40-45% carbohydrate and 15-20% protein. This diet is enriched with natural foods (fruits, vegetables, legumes, whole grain foods, fish, olive oil and oilseeds such as walnuts and almonds).~In addition, anthropometric measurements and body composition analysis of the participants were performed both at the beginning and at the end of the study, and some biochemical parameters (IL-6, TNF-α, CRP, MDA, TAS, TOS and routine blood parameters) were evaluated.
Study NCT04203121 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose whole brain radiation to treat Alzheimer disease
Description: subjects 1-5 : 9Gy in 5 daily fractions~subjects 6-10 : 5.4Gy in 3 daily fractions
Study NCT03891758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT-IPV-Hib
Description: 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Study NCT03891758 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib vaccine
Description: 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Study NCT03891758 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DPT-IPV
Description: 0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
Study NCT02848040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDK Bile Acids
Description: colourimetric in-vitro laboratory diagnostic test
Study NCT03747458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study NCT03198026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03198026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT00736086 — intervention group
Intervention type: DEVICE
Intervention: Vessel Closure (StarClose™)
Study NCT03198026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03382652 — intervention group
Intervention type: DEVICE
Intervention: Metal-on-Metal Articulation
Description: \<Metal-on-Metal Articulation>: Metasul® Taper Liner and Metasul Femoral Head, \<Acetabular Component>:Continuum Acetabular Shell, \<Femoral Component>: Zimmer® M/L Taper Hip Stem
Study NCT03811132 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
Study NCT03311490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spraino
Description: Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period.
Study NCT02346669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fat low fiber diet
Description: as detailed in arm description
Study NCT02854137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: 10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
Study NCT02854137 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: 10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
Study NCT03271385 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: evaluated by the predetermined differentiating formula
Description: After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
Study NCT02346669 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham diet
Description: as detailed in arm description
Study NCT02346669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low fat high fiber diet
Description: as detailed in arm description
Study NCT01251276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Process Hepatitis B Vaccine
Description: Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
Study NCT00538824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)
Study NCT00538824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
Study NCT00538824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~* Patients who demonstrate disease progression at any time will be taken off study.~* Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~* Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of \< 40cc/min\*
Study NCT01555112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical AS101
Description: AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
Study NCT00403559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elidel
Study NCT00403559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole Cream
Study NCT00931580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
Study NCT00931580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
Study NCT04897555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLLT
Description: This is a low-level light (LED) device configured in the shape of a headband, operating at 650 +/-10 nanometers and 940 +/- 10 nanometers, that contains 12 of each wavelength for a total of 24 LEDs.
Study NCT00618761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperglycemic clamp test
Description: hyperglycemic clamp test
Study NCT00618761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hyperglycemic clamp test
Description: hyperglycemic clamp test
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
Study NCT01764867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified electroconvulsive therapy
Description: Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
Study NCT01764867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT02572128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortified rice
Description: Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2.
Study NCT02436577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water
Description: Ticagrelor 90 mg OD tablet, single dose
Study NCT02436577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor OD tablet (90 mg single dose) administered without water
Description: Ticagrelor 90 mg OD tablet, single dose
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluvoxamine
Description: Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT00878462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine RED raspberry flavor (Treatment B)
Description: Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
Study NCT00878462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine WHITE UNFLAVORED (Treatment C)
Description: Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT01764867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study NCT00934596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lund de-airing technique
Description: In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV \& Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
Study NCT00934596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbon-dioxide insufflation
Description: In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
Study NCT02326974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Neoadjuvant treatment is for a total of 18 weeks.
Study NCT02436577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor IR tablet (90 mg) administered with 150 mL of water
Description: Ticagrelor 90 mg IR tablet, single dose
Study NCT02326974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Neoadjuvant treatment is for a total of 18 weeks.
Study NCT02326974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excision of tumor/mastectomy
Description: Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
Study NCT00966381 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise and weight loss intervention
Description: randomized control trial, stratified by parity
Study NCT00966381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and weight loss intervention
Description: randomized control trial, stratified by parity
Study NCT00894114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V520
Description: MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
Study NCT00894114 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Comparator: ALVAC-HIV vaccine
Description: A single dose 0.1 intramuscular injection
Study NCT00894114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: ALVAC-HIV vaccine
Description: A single dose 0.1 intramuscular injection
Study NCT02888080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
Study NCT02888080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
Study NCT01641549 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency surgery
Description: Emergency surgery (valve replacement or thrombectomy)
Study NCT01641549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinolytic therapy
Description: Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
Study NCT02822664 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pedophiles patients
Description: cerebral MRI and/or cerebral PET imaging
Study NCT02822664 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy subjects
Description: cerebral MRI and/or cerebral PET imaging
Study NCT02822664 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI
Study NCT02736071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure
Study NCT02245334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: 1 pill per biopsy
Study NCT04615299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
Study NCT04615299 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auricular acupuncture
Description: Auricular or Battlefield acupuncture is an auricular therapy which has been in existence for centuries, with roots tied to Eastern Asian medicine.
Study NCT04105777 — intervention group
Intervention type: DEVICE
Intervention: Parenteral Nutrition Bag Eurotube
Description: 7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
Study NCT04105777 — intervention group
Intervention type: DEVICE
Intervention: Parenteral Nutrition 2/3 chamber Bag
Description: Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
Study NCT01566526 — intervention group
Intervention type: DRUG
Intervention: dexamethasone intravitreal implant 0.7 mg
Description: OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
Study NCT02762617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate intravaginal ring
Description: The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
Study NCT05061342 — intervention group
Intervention type: OTHER
Intervention: No experimental interventions 1. Observation; 2. Anticancer treatments, including surgery, systemic therapy, radiotherapy, Chinese traditional medicine, or palliative/supportive care.
Description: Any anticancer or palliative care